blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1647556

EP1647556 - Peptidic compounds and derivatives thereof for the treatment of human diseases through inhibition of signaling via growth factors [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  25.03.2011
Database last updated on 07.10.2024
Most recent event   Tooltip13.09.2013Lapse of the patent in a contracting state
Updated state(s): BG		published on 16.10.2013  [2013/42]
Applicant(s)For all designated states
Karlsruher Institut für Technologie
Kaiserstrasse 12
76131 Karlsruhe / DE
[2009/50]
Former [2008/17]For all designated states
Forschungszentrum Karlsruhe GmbH
Herrmann-von-Helmholtz-Platz 1
76344 Eggenstein-Leopoldshafen / DE
Former [2006/16]For all designated states
TopoTarget Germany AG
Paul-Ehrlich-Strasse 42-44
60596 Frankfurt am Main / DE
For all designated states
Forschungszentrum Karlsruhe GmbH
Herrmann-von-Helmholtz-Platz 1
76344 Eggenstein-Leopoldshafen / DE
Inventor(s)01 / Hentsch, Bernd
Gaissacherstrasse 20
81371 München / DE
02 / Ponta, Helmut
Ringstrasse 55
76356 Weingarten / DE
03 / Herrlich, Peter A.
Vogelsang 8
76229 Karlsruhe / DE
04 / Matzke, Alexandra
Brendstrasse 81
75179 Pforzheim / DE
05 / Orian-Rousseau, Veronique
Rue de Betschdorf 22
67690 Rittershoffen / FR
06 / Adam, Jan
Adlerstrasse 42
76133 Karlsruhe / DE
 [2008/44]
Former [2006/16]01 / Hentsch, Bernd
Gervinusstrasse 8
60322 Frankfurt/Main / DE
02 / Ponta, Helmut
Ringstrasse 55
76356 Weingarten / DE
03 / Herrlich, Peter A.
Vogelsang 8
76229 Karlsruhe / DE
04 / Matzke, Alexandra
Brendstrasse 81
75179 Pforzheim / DE
05 / Orian-Rousseau, Veronique
Rue de Betschdorf 22
67690 Rittershoffen / FR
06 / Adam, Jan
Adlerstrasse 42
76133 Karlsruhe / DE
Representative(s)Keller, Günter, et al
Lederer & Keller
Patentanwälte Partnerschaft mbB
Unsöldstrasse 2
80538 München / DE
[N/P]
Former [2006/16]Keller, Günter, et al
Lederer & Keller Patentanwälte Prinzregentenstrasse 16
80538 München / DE
Application number, filing date04024507.814.10.2004
[2006/16]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP1647556
Date:19.04.2006
Language:EN
[2006/16]
Type: B1 Patent specification 
No.:EP1647556
Date:19.05.2010
Language:EN
[2010/20]
Search report(s)(Supplementary) European search report - dispatched on:EP17.05.2005
ClassificationIPC:C07K7/08, A61K38/08, G01N33/00, A61K38/04, A61K38/10
[2006/16]
CPC:
C07K14/70585 (EP)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2006/16]
Extension statesAL28.09.2006
HR28.09.2006
LT28.09.2006
LV28.09.2006
MK28.09.2006
TitleGerman:Peptidische Verbindungen und deren Ableitungen für die Behandllung von menschlichen Krankheiten durch Hemmung der Signalübertragung über Wachstumfaktoren[2006/16]
English:Peptidic compounds and derivatives thereof for the treatment of human diseases through inhibition of signaling via growth factors[2006/16]
French:Composés et dérivés peptidiques pour le traitement de maladies humaines par inhibition de la transmission du signal par des facteurs de croissances[2006/16]
Examination procedure18.09.2006Examination requested  [2006/44]
13.07.2007Despatch of a communication from the examining division (Time limit: M06)
23.01.2008Reply to a communication from the examining division
24.02.2009Despatch of a communication from the examining division (Time limit: M02)
30.04.2009Reply to a communication from the examining division
14.12.2009Communication of intention to grant the patent
26.03.2010Fee for grant paid
26.03.2010Fee for publishing/printing paid
Opposition(s)22.02.2011No opposition filed within time limit [2011/17]
Fees paidRenewal fee
30.10.2006Renewal fee patent year 03
27.09.2007Renewal fee patent year 04
31.03.2008Renewal fee patent year 05
29.09.2009Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY19.05.2010
CZ19.05.2010
EE19.05.2010
FI19.05.2010
PL19.05.2010
RO19.05.2010
SI19.05.2010
SK19.05.2010
TR19.05.2010
BG19.08.2010
GR20.08.2010
PT20.09.2010
LU14.10.2010
MC31.10.2010
HU20.11.2010
[2013/42]
Former [2012/47]BG19.05.2010
CY19.05.2010
CZ19.05.2010
EE19.05.2010
FI19.05.2010
PL19.05.2010
RO19.05.2010
SI19.05.2010
SK19.05.2010
TR19.05.2010
GR20.08.2010
PT20.09.2010
LU14.10.2010
MC31.10.2010
HU20.11.2010
Former [2012/44]BG19.05.2010
CY19.05.2010
CZ19.05.2010
EE19.05.2010
FI19.05.2010
PL19.05.2010
RO19.05.2010
SI19.05.2010
SK19.05.2010
GR20.08.2010
PT20.09.2010
LU14.10.2010
MC31.10.2010
HU20.11.2010
Former [2012/42]BG19.05.2010
CY19.05.2010
CZ19.05.2010
EE19.05.2010
FI19.05.2010
PL19.05.2010
RO19.05.2010
SI19.05.2010
SK19.05.2010
GR20.08.2010
PT20.09.2010
MC31.10.2010
HU20.11.2010
Former [2012/41]BG19.05.2010
CY19.05.2010
CZ19.05.2010
EE19.05.2010
FI19.05.2010
PL19.05.2010
RO19.05.2010
SI19.05.2010
SK19.05.2010
GR20.08.2010
PT20.09.2010
MC31.10.2010
Former [2011/24]CY19.05.2010
CZ19.05.2010
EE19.05.2010
FI19.05.2010
PL19.05.2010
RO19.05.2010
SI19.05.2010
SK19.05.2010
GR20.08.2010
PT20.09.2010
MC31.10.2010
Former [2011/10]CY19.05.2010
CZ19.05.2010
EE19.05.2010
FI19.05.2010
PL19.05.2010
RO19.05.2010
SI19.05.2010
SK19.05.2010
GR20.08.2010
PT20.09.2010
Former [2011/08]CY19.05.2010
EE19.05.2010
FI19.05.2010
PL19.05.2010
SI19.05.2010
GR20.08.2010
PT20.09.2010
Former [2011/05]CY19.05.2010
FI19.05.2010
PL19.05.2010
SI19.05.2010
GR20.08.2010
Former [2011/04]FI19.05.2010
PL19.05.2010
SI19.05.2010
GR20.08.2010
Former [2011/01]FI19.05.2010
SI19.05.2010
GR20.08.2010
Former [2010/52]FI19.05.2010
SI19.05.2010
Former [2010/50]FI19.05.2010
Documents cited:Search[A]US2003069181  (WONG ALBERT J [US]) [A] 1-20* the whole document *;
 [X]EP1391213  (BOEHRINGER INGELHEIM INT [DE]) [X] 1-3 * abstract *;
 [X]  - ORIAN-ROUSSEAU VÉRONIQUE ET AL, "CD44 is required for two consecutive steps in HGF/c-Met signaling.", GENES & DEVELOPMENT. 1 DEC 2002, (20021201), vol. 16, no. 23, ISSN 0890-9369, pages 3074 - 3086, XP002326889 [X] 1,2,18-20 * page 3078, column 1, paragraph 2 *

DOI:   http://dx.doi.org/10.1101/gad.242602
 [X]  - LACKNER CAROLIN ET AL, "Soluble CD44 v5 and v6 in serum of patients with breast cancer. Correlation with expression of CD44 v5 and v6 variants in primary tumors and location of distant metastasis", BREAST CANCER RESEARCH AND TREATMENT, (199801), vol. 47, no. 1, ISSN 0167-6806, pages 29 - 40, XP002326890 [X] 1,2,18 * abstract *

DOI:   http://dx.doi.org/10.1023/A:1005913514376
Examination   - A. MATZKE, ET AL., "A five-amino acid peptide blocks Met and Ron-dependent cell migration", CANCER RESEARCH, (20050715), vol. 64, no. 14, pages 6105 - 6110
by applicant   - MORRISON ET AL., GENES DEV, (2001), vol. 15, pages 968 - 80
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.